首页> Journal of hematology & oncology> Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.

Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.

导出 OA

翻译打印收藏纠错

第一作者： Yijun,Wu

第一单位： Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.;Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.;State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.;National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China.

作者： Yijun,Wu ^[1] ; Xu,Sun ^[2] ; Kai,Kang ^[3] ; Yuqi,Yang ^[4] ; He,Li ^[2] ; Ailin,Zhao ^[5] ; Ting,Niu ^[6]

作者单位： Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.;Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.;State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.;National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China. ^[1] Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.;State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.;National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China. ^[2] Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.;State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.;National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China. ^[3] West China School of Medicine, Sichuan University, Chengdu, Sichuan, China. ^[4] Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. zhaoailin@wchscu.cn.;State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China. zhaoailin@wchscu.cn.;National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China. zhaoailin@wchscu.cn. ^[5] Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. niuting@wchscu.cn.;State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China. niuting@wchscu.cn.;National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China. niuting@wchscu.cn. ^[6]

关键词 Cytokine storm Emapalumab Hemophagocytic lymphohistiocytosis Pathogenic mechanisms Targeted therapy

医学主题词淋巴组织细胞增多症, 嗜血细胞性(Lymphohistiocytosis, Hemophagocytic);人类(Humans);分子靶向治疗(Molecular Targeted Therapy);干扰素γ(Interferon-gamma);抗体, 单克隆(Antibodies, Monoclonal);抗体, 中和(Antibodies, Neutralizing)

DOI 10.1186/s13045-024-01621-x

PMID 39511607

发布时间 2025-05-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交